Skip to main content
Premium Trial:

Request an Annual Quote

Canada Clears Abbott HPV Molecular Diagnostic Test

NEW YORK (GenomeWeb News) – The Medical Device Bureau of Health Canada has granted a license to Abbott to market its RealTime High Risk HPV molecular diagnostic test for detecting human papillomavirus, Abbott announced today.

The test, which was CE marked in 2008, detects 14 high-risk HPV genotypes with simultaneous detection of HPV genotypes 16 and 18, which are known to pose the highest risk of progression to cervical cancer. About 70 percent of cervical cancer cases are found to have HPV 16 and/or 18, Abbott said.

The company's test is run on its m2000 RealTime molecular diagnostic system.

"HPV DNA tests, like the Abbott RealTime High Risk HPV test, combined with high specificity of cytology, can direct the appropriate management strategies for women with abnormal pap results," Judy Yu, director of scientific affairs, Molecular Diagnostics, Abbott, said in a statement.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.